Wolters Kluwer Pharma Solutions Signs 8-Year Lease on Corporate Headquarters for Healthcare Analytics

Wolters Kluwer Pharma Solutions Signs 8-Year Lease on Corporate Headquarters for Healthcare Analytics
Long Time Phoenix-Based Company to Remain in Biltmore Financial Center But Will Upgrade to New, High-Tech Space
PHOENIX (September 16, 2011) - Wolters Kluwer Pharma Solutions, a leading provider of scientific information and analytics to pharmaceutical and healthcare professionals, today announced the signing of an 8-year lease on 70,000 square feet of new office space in the Biltmore Financial Center office park in Phoenix, AZ. The company will move its Healthcare Analytics business in January 2012 from its current location to a new, innovative and technologically savvy space.
"With over 300 Phoenix-based employees and contractors, we wanted a space that allows us to build out collaborative workspaces, high tech conference rooms, and creative office solutions to meet the needs of our team and fuel innovation," stated Michelle Woker, President and Chief Operating Officer, Healthcare Analytics, Wolters Kluwer Pharma Solutions. "We're in the high-tech information industry and our new office space enables technology to better support our business."
The new building, located at 2390 E. Camelback Road, will initially house 320 staff, with space to grow for planned additional headcount. As the business's corporate headquarters, the building will be outfitted with nine high tech conference rooms, upgraded technology throughout the building, and new, multi-functional, collaborative workspaces. The business undertook an extensive assessment of staff work styles and productivity work flows to configure their office space and design plans.
Operating from this Phoenix location since 1992, the Wolters Kluwer Pharma Solutions Healthcare Analytics business provides leading-edge pharmaceutical market data as well as analytics and consulting. Its unique data offerings allow customers to analyze the industry from multiple perspectives including the provider, the payer and the patient.  It also is the only leading data provider to offer a view of the market that merges all three perspectives.
The lease, which begins on January 1, 2012, was brokered by Collier's International. The building is owned by the Florida Employees Pension Fund.
# # #
About Wolters Kluwer Pharma Solutions
Wolters Kluwer Pharma Solutions, Inc. (Phoenix, AZ and Yardley, PA) is a leading provider of information and analytics to the pharmaceutical, biotech, and medical device industries. The company's brands include Adis, Source® and Lippincott Williams & Wilkins. A provider of business intelligence and services, Adis publishes 19 peer-reviewed drug research journals and 2 newsletters and offers the most respected drug and clinical trials databases in the pharma industry. Lippincott Williams & Wilkins (LWW) is a leading international healthcare publisher with nearly 300 periodicals and 1,500 books in more than 100 disciplines. A longstanding provider of market data and healthcare analytics, Source® offers a unique set of comprehensive patient and physician-level prescribing and usage data. For more information, visit www.wolterskluwerpharma.com.
The company is a wholly owned subsidiary of Wolters Kluwer, U.S., part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer's leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer has 2010 annual revenues of €3.6 billion ($4.7 billion), employs approximately 18,200 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.
Thomas M. Kivett
Managing Director
Kivett & Company Communications, LLC
303 West 19th Street, 6th Fl.
New York, NY 10011
phone: (212) 727-2935
fax: (212) 727-2552
email: [email protected]
www.kivettandco.com

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.